TECP
PMN icon

Trails Edge Capital Partners’s ProMIS Neurosciences PMN Stock Holding History

Trails Edge Capital Partners’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.33M Hold
557,103
– – 1.16% 30
2026
Q1 		$7.08M Buy
+557,103
New +$8.31M 1.62% 22

Other funds holding PMN

JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Trails Edge Capital Partners's PMN Position: Q2 2026 in Review

Trails Edge Capital Partners held its ProMIS Neurosciences (PMN) position steady in Q2 2026 at 557,103 shares worth $7.33M. The position accounts for 1.16% of the portfolio, ranked #30.

Trails Edge Capital Partners first reported a position in PMN in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold PMN as of Q2 2026.

  • Trails Edge Capital Partners held 557,103 shares of ProMIS Neurosciences worth $7.33M as of Q2 2026.
  • Trails Edge Capital Partners left its ProMIS Neurosciences share count unchanged in Q2 2026.
  • ProMIS Neurosciences made up 1.16% of Trails Edge Capital Partners's portfolio in Q2 2026, its #30 holding.
  • Trails Edge Capital Partners first reported a position in ProMIS Neurosciences in Q1 2026 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.